Now showing items 21-30 of 98
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
(Elsevier/Science Direct, 2018-11-02)
BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...
Quantifying multiple sclerosis pathology in post mortem spinal cord using MRI.
Multiple sclerosis (MS) is a common inflammatory, demyelinating and degenerative disease of the central nervous system. The majority of people with MS present with symptoms due to spinal cord damage, and in more advanced ...